C. Robert Horsburgh, MD

Professor, Epidemiology
C. Horsburgh
(617) 638-7775rhorsbu@bu.edu
Talbot – T326E
View full profile at BUMC

Biography

Dr. Horsburgh has 30 years of experience in public health and medicine. He currently holds faculty positions in the Department of Biostatistics and the Department of Medicine. Dr. Horsburgh teaches courses in the Epidemiology of AIDS and the Epidemiology of Tuberculosis. He has focused his research on tuberculosis, nontuberculous mycobacterial infections and opportunistic infections in AIDS and has served as the National Steering Committee Co-Chairman of the Tuberculosis Trials Consortium and the Tuberculosis Epidemiologic Studies Consortium. He is currently the Chairman of the Steering Committee of RESIST-TB, an international organization dedicated to improving MDR-TB treatment through Clinical Trials.

Other Positions:

  • Professor of Epidemiology, Epidemiology, Boston University School of Public Health
  • Professor, Infectious Disease, Medicine, Boston University School of Medicine
  • Professor, Biostatistics, Boston University School of Public Health
  • Boston Medical Center

Education

  • Case Western Reserve University, MD
  • Yale University, MUS
  • Princeton University, AB

Classes Taught

  • SPHEP764
  • SPHEP784
  • SPHEP911
  • SPHEP912

Publications

  • Published on 3/1/2014

    Horsburgh CR. Tuberculosis. Eur Respir Rev. 2014 Mar 1; 23(131):36-9.

    Read at: PubMed
  • Published on 1/28/2014

    Linas BP, Barter DM, Leff JA, Dilorenzo M, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Freedberg KA. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS. 2014 Jan 28; 28(3):365-76.

    Read at: PubMed
  • Published on 10/25/2013

    Brigden G, Nyang''wa BT, du Cros P, Varaine F, Hughes J, Rich M, Horsburgh CR, Mitnick CD, Nuermberger E, McIlleron H, Phillips PP, Balasegaram M. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ. 2014 Jan 1; 92(1):68-74.

    Read at: PubMed
  • Published on 10/18/2013

    Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol. 2014 Jan 15; 179(2):216-25.

    Read at: PubMed
  • Published on 3/28/2013

    Horsburgh CR, Shea KM, Phillips P, Lavalley M. Randomized clinical trials to identify optimal antibiotic treatment duration. Trials. 2013; 14:88.

    Read at: PubMed
  • Published on 3/1/2013

    O'Donnell MR, Padayatchi N, Kvasnovsky C, Werner L, Master I, Horsburgh CR. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis. 2013 Mar; 19(3):416-24.

    Read at: PubMed
  • Published on 1/29/2013

    Hochberg NS, Horsburgh CR. Prevention of tuberculosis in older adults in the United States: obstacles and opportunities. Clin Infect Dis. 2013 May; 56(9):1240-7.

    Read at: PubMed
  • Published on 12/4/2012

    Horsburgh CR, Haxaire-Theeuwes M, Lienhardt C, Wingfield C, McNeeley D, Pyne-Mercier L, Keshavjee S, Varaine F. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2013 Feb; 17(2):146-52.

    Read at: PubMed
  • Published on 11/15/2012

    Reed C, Bliss C, Stuver SO, Heeren T, Tumilty S, Horsburgh CR, Samet JH, Cotton DJ. Predictors of active injection drug use in a cohort of patients infected with hepatitis C virus. Am J Public Health. 2013 Jan; 103(1):105-11.

    Read at: PubMed
  • Published on 12/8/2011

    Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR, Chaisson RE. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011 Dec 8; 365(23):2155-66.

    Read at: PubMed

View 58 more publications:View full profile at BUMC